Literature DB >> 23648420

Biochemical and immunological characteristics of Peruvian Loxosceles laeta spider venom: neutralization of its toxic effects by anti-loxoscelic antivenoms.

G Guimarães1, C Dias-Lopes, C G Duarte, L Felicori, R A Machado de Avila, L F M Figueiredo, J de Moura, B T Faleiro, J Barro, K Flores, W Silva, B Tintaya, A Yarleque, C Bonilla, E Kalapothakis, C E Salas, C Chávez-Olortegui.   

Abstract

This manuscript describes the general biochemical properties and immunological characteristics of Peruvian spider Loxosceles laeta venom (PLlv), which is responsible for the largest number of accidents involving venomous animals in Peru. In this work, we observed that the venom of this spider is more lethal to mice when compared with L. laeta venom from Brazil (BLlv). The LD₅₀ of PLlv was 1.213 mg/kg when the venom was intradermally injected. The venom displayed sphingomyelinase activity and produced dermonecrotic, hemorrhagic and edema effects in rabbits. 2-D SDS-PAGE separation of the soluble venoms resulted in a protein profile ranging from 20 to 205 kDa. Anti-PLlv and anti-BLlv sera produced in rabbits and assayed by ELISA showed that rabbit antibodies cross-reacted with PLlv and BLlv and also with other Brazilian Loxosceles venoms. Western blotting analysis showed that bands corresponding to 25-35 kDa are the proteins best recognized in every Loxosceles spp venoms analyzed. The immunized rabbits displayed protective effect after challenge with PLlv and BLlv. In vitro assays with horse anti-loxoscelic antivenoms produced in Brazil and Peru demonstrated that these commercial antivenoms were efficient to inhibit the sphingomyelinase activity of PLlv and BLlv.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23648420     DOI: 10.1016/j.toxicon.2013.04.018

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  3 in total

1.  Whole venom of Loxosceles similis activates caspases-3, -6, -7, and -9 in human primary skin fibroblasts.

Authors:  Arthur Estanislau Dantas; Carolina Campolina Rebello Horta; Thais M M Martins; Anderson Oliveira do Carmo; Bárbara Bruna Ribeiro de Oliveira Mendes; Alfredo M Goes; Evanguedes Kalapothakis; Dawidson A Gomes
Journal:  Toxicon       Date:  2014-04-12       Impact factor: 3.033

2.  Recombinant Protein Containing B-Cell Epitopes of Different Loxosceles Spider Toxins Generates Neutralizing Antibodies in Immunized Rabbits.

Authors:  Sabrina de Almeida Lima; Clara Guerra-Duarte; Fernanda Costal-Oliveira; Thais Melo Mendes; Luís F M Figueiredo; Daysiane Oliveira; Ricardo A Machado de Avila; Valéria Pereira Ferrer; Dilza Trevisan-Silva; Silvio S Veiga; João C Minozzo; Evanguedes Kalapothakis; Carlos Chávez-Olórtegui
Journal:  Front Immunol       Date:  2018-04-03       Impact factor: 7.561

3.  Design and Production of a Recombinant Hybrid Toxin to Raise Protective Antibodies Against Loxosceles Spider Venom.

Authors:  Paula A L Calabria; Lhiri Hanna A L Shimokava-Falcao; Monica Colombini; Ana M Moura-da-Silva; Katia C Barbaro; Eliana L Faquim-Mauro; Geraldo S Magalhaes
Journal:  Toxins (Basel)       Date:  2019-02-12       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.